REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 11 months 19 days ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 11 months 19 days ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 11 months 19 days ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 11 months 20 days ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 11 months 20 days ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 11 months 20 days ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 11 months 20 days ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 11 months 21 days ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 11 months 30 days ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 11 months 30 days ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 05/11/2026 at 14:30, 3 hours 16 minutes ago Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Published on 05/11/2026 at 14:00, 3 hours 46 minutes ago Unusual Machines Accelerates Domestic Battery Manufacturing by Signing a Merger Agreement to Acquire Upgrade Energy
Published on 05/11/2026 at 14:00, 3 hours 46 minutes ago New Horizon Aircraft Ltd. Announces Closing of $20 Million Offering of Common Shares
Published on 05/11/2026 at 14:00, 3 hours 46 minutes ago Colosseum Bankable Feasibility Study Confirms High Margin Gold Project
Published on 05/11/2026 at 14:00, 3 hours 46 minutes ago Ur-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and Webcast
Published on 05/11/2026 at 17:37, 9 minutes ago PATRIZIA reports strong EBITDA and net profit growth in the first three months of 2026
Published on 05/11/2026 at 17:21, 25 minutes ago Dassault Aviation and OHB team up to propose to ESA the VORTEX-S multipurpose space plane
Published on 05/11/2026 at 17:21, 25 minutes ago EQS-Adhoc: Allgeier SE: Allgeier boosts sales by 9 percent in the first quarter of 2026 and proposes a dividend of 1.00 Euro per share
Published on 05/11/2026 at 15:55, 1 hour 51 minutes ago EQS-Adhoc: Accentro Real Estate AG announces deviation from the IDW S6 report and intended increase in the 2025/2027 bond
Published on 05/11/2026 at 15:46, 1 hour 59 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/11/2026 at 17:36, 10 minutes ago Availability of Groupe des Assurances du Crédit Mutuel’s Solvency and Financial Condition Report
Published on 05/11/2026 at 17:36, 10 minutes ago Availability of the 2025 financial statements of Groupe des Assurances du Crédit Mutuel
Published on 05/11/2026 at 17:35, 11 minutes ago Déclaration hebdomadaire d'opérations effectuées du 4 au 8 mai 2026
Published on 05/11/2026 at 17:35, 11 minutes ago Disclosure of transactions in own shares from May 4 to May 8, 2026
